Duration of clopidogrel-based dual antiplatelet therapy and clinical outcomes after endeavor sprint zotarolimus-eluting stent implantation in patients presenting with acute coronary syndrome

European Journal of Internal Medicine

Volumn 26, Issue 7, 2015, Pages 521-527

  Song, Pil Sang ^a   Hahn, Joo Yong ^b   Kim, Doo Il ^a   Song, Young Bin ^b   Choi, Seung Hyuk ^b   Choi, Jin Ho ^b   Ryu, Dong Ryeol ^c   Hur, Seung Ho ^d   Jeong, Jin Ok ^e   Park, Hun Sik ^f   Kim, Hyo Soo ^g   Gwon, Hyeon Cheol ^b  

^a Inje University   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

^c Kangwon National University   (South Korea)

^d Dongsan Medical Center   (South Korea)

^e Chungnam National University   (South Korea)

^f Kyungpook National University Hospital   (South Korea)

^g Seoul National University Hospital   (South Korea)

Author keywords

Acute coronary syndrome; Dual antiplatelet therapy; Zotarolimus eluting stents

Indexed keywords

CLOPIDOGREL; CREATINE KINASE MB; TROPONIN T; ANTITHROMBOCYTIC AGENT; RAPAMYCIN; TICLOPIDINE; ZOTAROLIMUS;

ACUTE CORONARY SYNDROME; ADULT; ADVERSE OUTCOME; ARTICLE; CAUSE OF DEATH; CEREBRAL REVASCULARIZATION; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; HEART INFARCTION; HUMAN; INCIDENCE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PROPENSITY SCORE; STENT THROMBOSIS; TREATMENT DURATION; TREATMENT INDICATION; ZOTAROLIMUS ELUTING CORONARY STENT; AGED; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DRUG ELUTING STENT; KAPLAN MEIER METHOD; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROCEDURES; SOUTH KOREA; TREATMENT OUTCOME;

ACUTE CORONARY SYNDROME; AGED; CAUSE OF DEATH; DRUG-ELUTING STENTS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; REPUBLIC OF KOREA; SIROLIMUS; TICLOPIDINE; TREATMENT OUTCOME;

EID: 84941598947     PISSN: 09536205     EISSN: 18790828     Source Type: Journal    
DOI: 10.1016/j.ejim.2015.06.014     Document Type: Article

References (23)

1. S. Windecker, P. Kolh, F. Alfonso, J.P. Collet, J. Cremer, V. Falk, and et al. 2014 ESC/EACTS guidelines on myocardial revascularization Eur Heart J 35 2014 2541 2619
2. F. Feres, R.A. Costa, A. Abizaid, M.B. Leon, J.A. Marin-Neto, R.V. Botelho, and et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial JAMA 310 2013 2510 2522
3. H.C. Gwon, J.Y. Hahn, K.W. Park, Y.B. Song, I.H. Chae, D.S. Lim, and et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study Circulation 125 2012 505 513
4. B.K. Kim, M.K. Hong, D.H. Shin, C.M. Nam, J.S. Kim, Y.G. Ko, and et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation) J Am Coll Cardiol 60 2012 1340 1348
5. K. Thygesen, J.S. Alpert, A.S. Jaffe, M.L. Simoons, B.R. Chaitman, H.D. White, and et al. Third universal definition of myocardial infarction Circulation 126 2012 2020 2035
6. D.E. Cutlip, S. Windecker, R. Mehran, A. Boam, D.J. Cohen, G.A. van Es, and et al. Clinical end points in coronary stent trials: a case for standardized definitions Circulation 115 2007 2344 2351
7. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, K.K. Fox, and et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
8. E.L. Eisenstein, K.J. Anstrom, D.F. Kong, L.K. Shaw, R.H. Tuttle, D.B. Mark, and et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation JAMA 297 2007 159 168
9. H. Daida, K. Miyauchi, H. Ogawa, H. Yokoi, M. Matsumoto, M. Kitakaze, and et al. Management and two-year long-term clinical outcome of acute coronary syndrome in Japan: prevention of atherothrombotic incidents following ischemic coronary attack (PACIFIC) registry Circ J 77 2013 934 943
10. J. Fajadet, W. Wijns, G.J. Laarman, K.H. Kuck, J. Ormiston, S. Baldus, and et al. Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study EuroIntervention 6 2010 562 567
11. L. Mauri, J.M. Massaro, S. Jiang, I. Meredith, W. Wijns, J. Fajadet, and et al. Long-term clinical outcomes with zotarolimus-eluting versus bare-metal coronary stents JACC Cardiovasc Interv 3 2010 1240 1249
12. J.Y. Hahn, Y.B. Song, J.H. Choi, S.H. Choi, S.Y. Lee, H.S. Park, and et al. Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry Circ J 74 2010 2314 2321
13. J.S. Kim, I.K. Jang, C. Fan, T.H. Kim, J.S. Kim, S.M. Park, and et al. Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial JACC Cardiovasc Interv 2 2009 1240 1247
14. J.W. Kim, H.S. Seo, J.H. Park, J.O. Na, C.U. Choi, H.E. Lim, and et al. A prospective, randomized, 6-month comparison of the coronary vasomotor response associated with a zotarolimus- versus a sirolimus-eluting stent: differential recovery of coronary endothelial dysfunction J Am Coll Cardiol 53 2009 1653 1659
15. C. Varenhorst, K. Jensevik, T. Jernberg, A. Sundstrom, P. Hasvold, C. Held, and et al. Duration of dual antiplatelet treatment with clopidogrel and aspirin in patients with acute coronary syndrome Eur Heart J 35 2014 969 978
16. L. Mauri, D.J. Kereiakes, R.W. Yeh, P. Driscoll-Shempp, D.E. Cutlip, P.G. Steg, and et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents N Engl J Med 371 2014 2155 2166
17. F. Costa, P. Vranckx, S. Leonardi, E. Moscarella, G. Ando, P. Calabro, and et al. Impact of clinical presentation on ischaemic and bleeding outcomes in patients receiving 6- or 24-month duration of dual-antiplatelet therapy after stent implantation: a pre-specified analysis from the PRODIGY (Prolonging Dual-Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia) trial Eur Heart J 36 20 Feb 25 2015 1242 1251
18. M. Gilard, P. Barragan, A.A. Noryani, H.A. Noor, T. Majwal, T. Hovasse, and et al. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial J Am Coll Cardiol Nov 16 2014 10.1016/j.jacc.2014.11.008 (pii: S0735-1097(14)06970-8.[Epub ahead of print])
19. G. Ndrepepa, S. Schulz, F.J. Neumann, K.L. Laugwitz, G. Richardt, R.A. Byrne, and et al. Prognostic value of bleeding after percutaneous coronary intervention in patients with diabetes EuroIntervention 10 2014 83 89
20. P.G. Steg, K. Huber, F. Andreotti, H. Arnesen, D. Atar, L. Badimon, and et al. Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology Eur Heart J 32 2011 1854 1864
21. F. Bonhomme, P. Fontana, and J.L. Reny How to manage prasugrel and ticagrelor in daily practice Eur J Intern Med 25 2014 213 220
22. M. Valgimigli, M. Borghesi, M. Tebaldi, P. Vranckx, G. Parrinello, and R. Ferrari Should duration of dual antiplatelet therapy depend on the type and/or potency of implanted stent? A pre-specified analysis from the PROlonging Dual antiplatelet treatment after Grading stent-induced Intimal hyperplasia studY (PRODIGY) Eur Heart J 34 2013 909 919
23. M. Ranucci, S. Castelvecchio, L. Menicanti, A. Frigiola, and G. Pelissero Risk of assessing mortality risk in elective cardiac operations: age, creatinine, ejection fraction, and the law of parsimony Circulation 119 2009 3053 3061